Lu Zhang1, Qingzhao Yu2, Xiao-Cheng Wu1, Mei-Chin Hsieh1, Michelle Loch3, Vivien W Chen1, Elizabeth Fontham1, Tekeda Ferguson4. 1. Epidemiology program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 2. Biostatistics program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 3. School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 4. Epidemiology program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. Tferg4@lsuhsc.edu.
Abstract
PURPOSE: To investigate the impact of chemotherapy relative dose intensity (RDI) on cause-specific and overall survival for stage I-III breast cancer: estrogen receptor or progesterone receptor positive, human epidermal-growth factor receptor negative (ER+/PR+ and HER2-) vs. triple-negative (TNBC) and to identify the optimal RDI cut-off points in these two patient populations. METHODS: Data were collected by the Louisiana Tumor Registry for two CDC-funded projects. Women diagnosed with stage I-III ER+/PR+, HER2- breast cancer, or TNBC in 2011 with complete information on RDI were included. Five RDI cut-off points (95, 90, 85, 80, and 75%) were evaluated on cause-specific and overall survival, adjusting for multiple demographic variables, tumor characteristics, comorbidity, use of granulocyte-growth factor/cytokines, chemotherapy delay, chemotherapy regimens, and use of hormone therapy. Cox proportional hazards models and Kaplan-Meier survival curves were estimated and adjusted by stabilized inverse probability treatment weighting (IPTW) of propensity score. RESULTS: Of 494 ER+/PR+, HER2- patients and 180 TNBC patients, RDI < 85% accounted for 30.4 and 27.8%, respectively. Among ER+/PR+, HER2- patients, 85% was the only cut-off point at which the low RDI was significantly associated with worse overall survival (HR = 1.93; 95% CI 1.09-3.40). Among TNBC patients, 75% was the cut-off point at which the high RDI was associated with better cause-specific (HR = 2.64; 95% CI 1.09, 6.38) and overall survival (HR = 2.39; 95% CI 1.04-5.51). CONCLUSIONS: Higher RDI of chemotherapy is associated with better survival for ER+/PR+, HER2- patients and TNBC patients. To optimize survival benefits, RDI should be maintained ≥ 85% in ER+/PR+, HER2- patients, and ≥ 75% in TNBC patients.
PURPOSE: To investigate the impact of chemotherapy relative dose intensity (RDI) on cause-specific and overall survival for stage I-III breast cancer: estrogen receptor or progesterone receptor positive, human epidermal-growth factor receptor negative (ER+/PR+ and HER2-) vs. triple-negative (TNBC) and to identify the optimal RDI cut-off points in these two patient populations. METHODS: Data were collected by the Louisiana Tumor Registry for two CDC-funded projects. Women diagnosed with stage I-III ER+/PR+, HER2- breast cancer, or TNBC in 2011 with complete information on RDI were included. Five RDI cut-off points (95, 90, 85, 80, and 75%) were evaluated on cause-specific and overall survival, adjusting for multiple demographic variables, tumor characteristics, comorbidity, use of granulocyte-growth factor/cytokines, chemotherapy delay, chemotherapy regimens, and use of hormone therapy. Cox proportional hazards models and Kaplan-Meier survival curves were estimated and adjusted by stabilized inverse probability treatment weighting (IPTW) of propensity score. RESULTS: Of 494 ER+/PR+, HER2- patients and 180 TNBC patients, RDI < 85% accounted for 30.4 and 27.8%, respectively. Among ER+/PR+, HER2- patients, 85% was the only cut-off point at which the low RDI was significantly associated with worse overall survival (HR = 1.93; 95% CI 1.09-3.40). Among TNBC patients, 75% was the cut-off point at which the high RDI was associated with better cause-specific (HR = 2.64; 95% CI 1.09, 6.38) and overall survival (HR = 2.39; 95% CI 1.04-5.51). CONCLUSIONS: Higher RDI of chemotherapy is associated with better survival for ER+/PR+, HER2- patients and TNBC patients. To optimize survival benefits, RDI should be maintained ≥ 85% in ER+/PR+, HER2- patients, and ≥ 75% in TNBC patients.
Authors: Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman Journal: Breast Cancer Res Treat Date: 2006-05-17 Impact factor: 4.872
Authors: Vivien W Chen; Christie R Eheman; Christopher J Johnson; Monique N Hernandez; David Rousseau; Timothy S Styles; Dee W West; Meichin Hsieh; Anne M Hakenewerth; Maria O Celaya; Randi K Rycroft; Jennifer M Wike; Melissa Pearson; Judy Brockhouse; Linda G Mulvihill; Kevin B Zhang Journal: J Registry Manag Date: 2014
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Gary H Lyman; David C Dale; Dianne Tomita; Sadie Whittaker; Jeffrey Crawford Journal: Breast Cancer Res Treat Date: 2013-06-16 Impact factor: 4.872
Authors: Hee Jin Lee; In Hye Song; An Na Seo; Bora Lim; Joo Young Kim; Jeong-Ju Lee; In Ah Park; Jinho Shin; Jong Han Yu; Jin-Hee Ahn; Gyungyub Gong Journal: Ann Surg Oncol Date: 2014-09-06 Impact factor: 5.344
Authors: Sibylle Loibl; Tomas Skacel; Valentina Nekljudova; Hans Joachim Lück; Matthias Schwenkglenks; Thomas Brodowicz; Christoph Zielinski; Gunter von Minckwitz Journal: BMC Cancer Date: 2011-04-12 Impact factor: 4.430
Authors: Catherine Duggan; Allison Dvaladze; Anne F Rositch; Ophira Ginsburg; Cheng-Har Yip; Susan Horton; Rolando Camacho Rodriguez; Alexandru Eniu; Miriam Mutebi; Jean-Marc Bourque; Shahla Masood; Karla Unger-Saldaña; Anna Cabanes; Robert W Carlson; Julie R Gralow; Benjamin O Anderson Journal: Cancer Date: 2020-05-15 Impact factor: 6.860
Authors: Oluwatosin A Ayeni; Daniel S O'Neil; Yoanna S Pumpalova; Wenlong Carl Chen; Sarah Nietz; Boitumelo Phakathi; Ines Buccimazza; Sharon Čačala; Laura W Stopforth; Hayley A Farrow; Witness Mapanga; Maureen Joffe; Tobias Chirwa; Valerie McCormack; Judith S Jacobson; Katherine D Crew; Alfred I Neugut; Paul Ruff; Herbert Cubasch Journal: Int J Cancer Date: 2022-03-04 Impact factor: 7.316
Authors: Lauren A Marcath; Kelley M Kidwell; Kiran Vangipuram; Christina L Gersch; James M Rae; Monika L Burness; Jennifer J Griggs; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Br J Clin Pharmacol Date: 2020-02-04 Impact factor: 4.335
Authors: Ki-Yong An; Fernanda Z Arthuso; Dong-Woo Kang; Andria R Morielli; Stephanie M Ntoukas; Christine M Friedenreich; Donald C McKenzie; Karen Gelmon; John R Mackey; Kerry S Courneya Journal: Breast Cancer Res Treat Date: 2021-03-29 Impact factor: 4.872
Authors: Ilana Usiskin; Fangyong Li; Melinda L Irwin; Brenda Cartmel; Tara Sanft Journal: Breast Cancer Res Treat Date: 2020-10-30 Impact factor: 4.872